Northeast Financial Consultants Inc acquired a new stake in shares of Gelesis Holdings, Inc. (NYSE:GLS – Get Rating) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 35,000 shares of the company's stock, valued at approximately $158,000. Northeast Financial Consultants Inc owned about 0.10% of Gelesis at the end of the most recent reporting period.
Gelesis Trading Up 2.5 %
Gelesis stock opened at $1.21 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.62 and a debt-to-equity ratio of 5.89. Gelesis Holdings, Inc. has a 1 year low of $1.01 and a 1 year high of $12.23. The firm's 50 day moving average price is $1.44 and its 200-day moving average price is $3.23.
Get Gelesis alerts:Insider Activity
In related news, Director Raju S. Kucherlapati acquired 24,625 shares of Gelesis stock in a transaction dated Wednesday, June 15th. The shares were purchased at an average price of $1.95 per share, for a total transaction of $48,018.75. Following the completion of the transaction, the director now directly owns 90,264 shares in the company, valued at approximately $176,014.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Gelesis Profile
(Get Rating)Gelesis Holdings Inc, a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.
Featured Stories
- Get a free copy of the StockNews.com research report on Gelesis (GLS)
- How will the chip ban affect Nvidia's stock?
- Is Best Buy A Sneaky Buy for Q4?
- Does The Bed Bath and Beyond Stock Rally Still Have Legs?
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
Receive News & Ratings for Gelesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelesis and related companies with MarketBeat.com's FREE daily email newsletter.